Clene Inc CLNN

SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. 5th Annual ROTH Healthcare Opportunities ConferenceDate: September 29, 2026Location: New York, NYFormat: 1x1 meetings1x1 Meetings: Please contact your ROTH representative Lytham Partners Investor Conferenc

Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering was priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027, which is beyond the potential FDA decision to accept the CNM-Au8® NDA for review under the accelerated approval pathway SALT LAKE CITY, Sept. 21, 2026

Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing

SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences. 2026 Cantor Global Healthcare ConferenceDate: September 9, 2026Time of Presentation: 9:10am ETLocation: New York, NYFormat: Presentation and 1x1 meetings1x1 Meetings: Please contact your Cantor representativeWe

MIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 19, 2026Time of Presentation: 3:10 p.m. ETFormat: Corporate update A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1764701&tp_key=7a35454f76&sti=clnn.

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We plan to submit our new drug application (NDA) for CNM-Au8 under

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings. Date: Aug

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.

In the last week, the United States market has stayed flat, yet it is up 24% over the past year, with earnings expected to grow by 17% per annum over the next few years. In this environment, stocks with strong growth potential and high insider ownership can be particularly appealing as they may indicate confidence from those most familiar with the company's prospects.

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable rise of 24% over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of steady market performance and promising growth expectations, identifying stocks with high insider ownership can be a key factor for investors seeking companies where management's interests are closely aligned with those of shareholders.